MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases

Description

The purpose of this study is to test whether an additional magnetic resonance image (MRI) sequence can improve the ability to distinguish radiation damage from tumor recurrence in participants with brain metastasis who have previously been treated with stereotactic radiosurgery (SRS).

Conditions

Brain Metastases

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to test whether an additional magnetic resonance image (MRI) sequence can improve the ability to distinguish radiation damage from tumor recurrence in participants with brain metastasis who have previously been treated with stereotactic radiosurgery (SRS).

Diagnostic Accuracy of Delayed MRI Contrast Enhancement Characteristics and Radiation Necrosis Following Stereotactic Radiosurgery (SRS) for Brain Metastases

MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases

Condition
Brain Metastases
Intervention / Treatment

-

Contacts and Locations

Durham

Duke University Health System, Durham, North Carolina, United States, 27710

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult patients, age ≥18
  • * Metastatic malignancy with at least 1 brain metastasis previously treated with SRS
  • * Patients may have also received whole brain radiation therapy (WBRT) for management of brain metastatic disease but this is not required for study participation
  • * Patients must have been diagnosed with a metastatic solid tumor of any histological type except small cell lung cancer (SCLC), or lymphoma.
  • * Radiographic progression on post-SRS imaging at previously treated SRS site(s)
  • * Must be a candidate for brain surgery as determined by treating neurosurgeon and/or anesthesia team
  • * Patients must sign study-specific informed consent prior to study entry
  • * Poor surgical candidate as determined by treating neurosurgeon and/or anesthesia team
  • * Unable to undergo contrasted MRI (e.g. incompatible medical device, inadequate renal function per standard institutional clinical protocol, contrast allergy)
  • * Small cell lung cancer (SCLC) or lymphoma histology

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Duke University,

Scott Floyd, M.D. Ph.D., PRINCIPAL_INVESTIGATOR, Duke Health

Study Record Dates

2025-07